Rational Advisors LLC Incyte Corp Transaction History

Rational Advisors LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 05, 2021	SELL	$80.74 - $97.7 $6,297 - $7,620	-78 Closed	0 $0
Q3 2020 Nov 12, 2020	BUY	$85.07 - $109.69 $4,934 - $6,362	58 Added 290.0%	78 $7,000
Q2 2020 Aug 10, 2020	SELL	$74.18 - $108.93 $503,385 - $739,198	-6,786 Reduced 99.71%	20 $2,000
Q1 2020 May 12, 2020	BUY	$63.18 - $85.97 $349,069 - $474,984	5,525 Added 431.3%	6,806 $498,000
Q4 2019 Feb 06, 2020	BUY	$73.04 - $95.72 $83,192 - $109,025	1,139 Added 802.11%	1,281 $112,000
Q3 2019 Nov 06, 2019	BUY	$72.82 - $86.52 $4,660 - $5,537	64 Added 82.05%	142 $11,000
Q2 2019 Aug 08, 2019	SELL	$73.52 - $88.7 $1.98 Million - $2.39 Million	-26,989 Reduced 99.71%	78 $7,000
Q1 2019 May 08, 2019	BUY	$63.56 - $88.17 $1.72 Million - $2.38 Million	27,040 Added 100148.15%	27,067 $2.33 Million
Q4 2018 Feb 07, 2019	SELL	$58.5 - $69.94 $12,928 - $15,456	-221 Reduced 89.11%	27 $2,000
Q3 2018 Nov 08, 2018	BUY	$61.75 - $74.23 $14,820 - $17,815	240 Added 3000.0%	248 $17,000
Q2 2018 Aug 07, 2018	SELL	$60.85 - $83.98 $60 - $83	-1 Reduced 11.11%	8 $1,000
Q1 2018 May 18, 2018	BUY	$83.06 - $100.98 $747 - $908	9 New	9 $1,000

697

188M

585K

410K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $15.7B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Rational Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Rational Advisors LLC with notifications on news.